New York State Teachers Retirement System Cuts Position in Abbott Laboratories (NYSE:ABT)

New York State Teachers Retirement System reduced its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 3.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,635,521 shares of the healthcare product maker's stock after selling 51,688 shares during the period. New York State Teachers Retirement System owned about 0.09% of Abbott Laboratories worth $186,466,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in ABT. Vanguard Group Inc. increased its stake in shares of Abbott Laboratories by 5.6% during the first quarter. Vanguard Group Inc. now owns 165,301,921 shares of the healthcare product maker's stock worth $18,788,216,000 after purchasing an additional 8,834,840 shares in the last quarter. Capital International Investors raised its position in shares of Abbott Laboratories by 9.1% in the first quarter. Capital International Investors now owns 70,177,564 shares of the healthcare product maker's stock valued at $7,976,382,000 after buying an additional 5,882,780 shares during the last quarter. Ameriprise Financial Inc. boosted its position in Abbott Laboratories by 5.0% during the second quarter. Ameriprise Financial Inc. now owns 10,675,827 shares of the healthcare product maker's stock worth $1,103,997,000 after acquiring an additional 508,524 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Abbott Laboratories by 27.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 7,428,752 shares of the healthcare product maker's stock valued at $771,940,000 after acquiring an additional 1,596,835 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Abbott Laboratories by 7.7% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,352,134 shares of the healthcare product maker's stock worth $721,984,000 after purchasing an additional 452,308 shares in the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Barclays increased their price target on Abbott Laboratories from $140.00 to $143.00 and gave the company an "overweight" rating in a report on Monday, July 29th. Citigroup lifted their price target on Abbott Laboratories from $119.00 to $127.00 and gave the stock a "buy" rating in a report on Thursday, August 22nd. Morgan Stanley raised their price objective on shares of Abbott Laboratories from $107.00 to $117.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 17th. Edward Jones lowered shares of Abbott Laboratories from a "buy" rating to a "hold" rating in a report on Tuesday, July 30th. Finally, Piper Sandler Companies began coverage on shares of Abbott Laboratories in a research report on Thursday, September 19th. They set an "overweight" rating and a $131.00 price target on the stock. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $129.67.

Abbott Laboratories Trading Down 0.0 %

Shares of ABT stock traded down $0.03 on Wednesday, hitting $113.37. The stock had a trading volume of 403,361 shares, compared to its average volume of 5,685,763. The company's 50 day moving average price is $114.73 and its 200-day moving average price is $108.70. Abbott Laboratories has a 1 year low of $92.43 and a 1 year high of $121.64. The firm has a market capitalization of $197.22 billion, a P/E ratio of 35.33, a P/E/G ratio of 2.74 and a beta of 0.72. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.68 and a quick ratio of 1.18.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.01. Abbott Laboratories had a net margin of 13.65% and a return on equity of 20.18%. The business had revenue of $10.64 billion for the quarter, compared to analysts' expectations of $10.55 billion. During the same quarter in the prior year, the company earned $1.14 earnings per share. The business's quarterly revenue was up 4.9% on a year-over-year basis. Analysts anticipate that Abbott Laboratories will post 4.66 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, November 15th. Investors of record on Tuesday, October 15th will be paid a dividend of $0.55 per share. The ex-dividend date of this dividend is Tuesday, October 15th. This represents a $2.20 annualized dividend and a yield of 1.94%. Abbott Laboratories's payout ratio is 68.54%.

Insiders Place Their Bets

In related news, CEO Robert B. Ford sold 141,679 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $116.41, for a total value of $16,492,852.39. Following the completion of the transaction, the chief executive officer now owns 220,059 shares in the company, valued at $25,617,068.19. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.10% of the stock is owned by company insiders.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.